Title: Method and Medicament for Inhibiting the Expression of a Given Gene
Patent Number: 8,119,608
Filed: March 6, 2003
Lead Inventor: Roland Kreutzer, Alnylam Pharmaceuticals
The invention, the patent's abstract states, “provides methods and compositions for inhibiting gene expression using double-stranded RNA molecules that are between 15 and 24 nucleotides in length and are complementary to a target gene sequence.”
Title: Method for Efficient RNA Interference in Mammalian Cells
Patent Number: 8,119,610
Filed: May 29, 2003
Lead Inventor: Dun Yang, University of California, Oakland
The invention relates to “methods of making RNAi libraries using E. coli RNAse III for inhibition of mammalian gene expression,” the patent's abstract states.
Title: Treatment of Neurodegenerative Disease Through Intracranial Delivery of siRNA
Patent Number: 8,119,611
Filed: Aug. 27, 2009
Inventor: William Kaemmerer, Medtronic
The invention comprises “devices, small interfering RNA, and methods for treating a neurodegenerative disorder … [by] surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein,” the patent's abstract states. The invention also “provides valuable small interfering RNA vectors and methods for treating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, spinocerebellar ataxia type 1, type 2, type 3, and/or dentatorubral-pallidoluysian atrophy.”
Title: RNAi Inhibition of Alpha-EnaC Expression
Patent Number: 8,119,612
Filed: April 30, 2010
Lead Inventor: Gino Van Heeke, Novartis
“The invention relates to compositions and methods for modulating the expression of alpha-ENaC and, more particularly, to the down-regulation of alpha-ENaC expression by chemically modified oligonucleotides,” the patent's abstract states.
Title: siRNA-Mediated Gene Silencing Technology to Inhibit Tyrosinase and Reduce Pigmentation
Patent Number: 8,119,791
Filed: Jan. 29, 2009
Lead Inventor: Ralph Binetti, Avon Products
The invention, the patent's abstract states, comprises “compositions and methods for treating, preventing, and improving hyperpigmentation or [eliminating] unwanted pigmentation of the skin or other unwanted skin condition, such as age spots, aged skin, skin discoloration, etc.”
The compositions include siRNA ... specific for tyrosinase … [and] are used to treat a broad variety of pigmentation conditions, and are preferably applied to the skin, or are delivered by directed means to a site in need thereof,” the abstract adds.
Title: Compositions and Methods for siRNA Inhibition of Angiopoietin 1 and 2 and Their Receptor Tie2
Application Number: 20120039986
Filed: June 20, 2011
Lead Inventor: Samuel Reich, University of Pennsylvania (Opko Health)
The invention, the patent application's abstract states, relates to “RNA interference using small interfering RNAs, which are specific for mRNA produced from the Ang1, Ang2, or Tie2 genes [and inhibit] expression of these genes. Diseases which involve Ang1-, Ang2-, or Tie2-mediated angiogenesis, such as inflammatory and autoimmune diseases, diabetic retinopathy, age-related macular degeneration, and many types of cancer, can be treated by administering the small interfering RNAs.”
Title: Reduced Size Self-Delivering RNAi Compounds
Application Number: 20120040459
Filed: Sept. 22, 2009
Lead Inventor: Anastasia Khvorova, RXi Pharmaceuticals
The invention, the patent application's abstract states, relates to “RNAi constructs with minimal double-stranded regions and their use in gene silencing. RNAi constructs associated with the invention include a double-stranded region of 8 [to] 14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.”
Title: Ribonucleic Acid Interference Molecules
Application Number: 20120040460
Filed: Oct. 27, 2011
Lead Inventor: Isidore Rigoutsos, International Business Machines
The invention, the patent application's abstract states, comprises “ribonucleic acid interference molecules.”
Title: miRNA Targets
Application Number: 20120040851
Filed: Sept. 18, 2009
Lead Inventor: Judy Lieberman, Harvard University
The invention provides “systems for identifying, isolating, and/or characterizing targets of microRNAs,” according to the patent application's abstract.
Title: Compositions and Methods Relating to miR-31
Application Number: 20120041048
Filed: Dec. 7, 2009
Lead Inventor: Robert Weinberg, Whitehead Institute for Biomedical Research
The patent application, its abstract states, claims “microRNA-31, targets of miR-31, the role of miR-31 in inhibiting tumor metastasis, and the role of miR-31 target genes in promoting tumor metastasis.”
Title: Design of Small Interfering RNA
Application Number: 20120041049
Filed: Feb. 24, 2010
Inventor: Jacques Rohayem, Riboxx
The invention, the patent application's abstract states, “relates to small-interfering RNA molecules displaying an increased thermodynamic stability at the 3' end of the antisense strand and the 5' end of the sense strand, respectively, in comparison to the base pairing in the seed region. The siRNAs of the ... invention display an increased knockdown activity against targeted genes and show an improved resistance to RNAses, in particular serum RNAses. The ... invention also relates to a method for the production of the siRNA molecules, a method of target-specific RNA interference making use of the improved siRNA molecules of the invention, and pharmaceutical compositions containing the siRNA molecules.”
Title: Compositions and Methods for Inhibiting Expression of MIG-12 Gene
Application Number: 20120041051
Filed: Feb. 25, 2010
Lead Inventor: Kevin Fitzgerald, Alnylam Pharmaceuticals
“The invention relates to a double-stranded ribonucleic acid targeting MIDI interacting G12-like protein gene, and methods of using the dsRNA to inhibit expression of MIG 12,” according to the patent application's abstract.
Title: Compositions and Methods to Treat Muscular and Cardiovascular Disorders
Application Number: 20120041052
Filed: Aug. 9, 2011
Lead Inventor: Iwan Beuvink, Novartis
The invention relates to “a novel microRNA, miR-208-2, implicated in muscular and cardiovascular disorders,” the patent application's abstract states. The invention also relates to “oligonucleotide therapeutic agents and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of miR-208-2.”
Title: RNA Interference-Mediated Inhibition of Human Immunodeficiency Virus Gene Expression Using Short Interfering Nucleic Acid
Application Number: 20120041184
Filed: July 11, 2011
Lead Inventor: Leonid Beigelman, Merck
“This invention relates to compounds, compositions, and methods useful for modulating human immunodeficiency virus gene expression using short interfering nucleic acid molecules,” the patent application's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of human immunodeficiency virus gene expression and/or activity by RNA interference using small nucleic acid molecules.”